Aura Biosciences/$AURA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aura Biosciences
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Ticker
$AURA
Sector
Primary listing
Employees
108
Headquarters
Website
Aura Biosciences Metrics
BasicAdvanced
$396M
-
-$1.95
0.46
-
Price and volume
Market cap
$396M
Beta
0.46
52-week high
$10.81
52-week low
$4.35
Average daily volume
320K
Financial strength
Current ratio
12.386
Quick ratio
11.939
Long term debt to equity
8.542
Total debt to equity
10.372
Profitability
EBITDA (TTM)
-107.506
Effective tax rate (TTM)
-0.13%
Management effectiveness
Return on assets (TTM)
-32.14%
Return on equity (TTM)
-55.39%
Valuation
Price to book
2.26
Price to tangible book (TTM)
2.26
Price to free cash flow (TTM)
-3.929
Free cash flow yield (TTM)
-25.45%
Free cash flow per share (TTM)
-1.621
Growth
Earnings per share change (TTM)
9.96%
3-year earnings per share growth (CAGR)
-9.64%
What the Analysts think about Aura Biosciences
Analyst ratings (Buy, Hold, Sell) for Aura Biosciences stock.
Bulls say / Bears say
Bel-sar is in a global Phase III CoMpass trial for first-line treatment of early-stage choroidal melanoma, positioning AURA to potentially capture a vision-sparing therapy market earlier in disease progression (Financial Times)
Orphan and Fast Track designations for bel-sar should expedite development and grant market exclusivity, supported by orphan drugs commanding high returns and regulatory incentives such as 7-year US and 10-year EU exclusivity (Financial Times)
The company’s virus-like particle (VLP) platform allows conjugation with cytotoxic payloads or nucleic acids, enabling a versatile therapeutic pipeline targeting multiple solid tumors beyond ocular oncology, underpinning future growth prospects (Financial Times)
Dependence on a single late-stage asset bel-sar exposes AURA to binary risk; any setback in the Phase III CoMpass trial could severely impair valuation due to lack of alternative revenue drivers (Bloomberg)
AURA reported zero revenue (TTM) and a net loss of $101.38 million, indicating significant cash burn and likely need for dilutive funding absent near-term approvals, pressuring share value (Financial Times)
Orphan drugs face stringent pricing and reimbursement scrutiny, with bodies like NICE rejecting treatments costing over £100,000 per QALY, potentially limiting bel-sar’s commercial uptake in key European markets (Financial Times)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
Aura Biosciences Financial Performance
Revenues and expenses
Aura Biosciences Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aura Biosciences stock?
Aura Biosciences (AURA) has a market cap of $396M as of October 29, 2025.
What is the P/E ratio for Aura Biosciences stock?
The price to earnings (P/E) ratio for Aura Biosciences (AURA) stock is 0 as of October 29, 2025.
Does Aura Biosciences stock pay dividends?
No, Aura Biosciences (AURA) stock does not pay dividends to its shareholders as of October 29, 2025.
When is the next Aura Biosciences dividend payment date?
Aura Biosciences (AURA) stock does not pay dividends to its shareholders.
What is the beta indicator for Aura Biosciences?
Aura Biosciences (AURA) has a beta rating of 0.46. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.